Clinical Trials

Current FDA-authorized clinical trials either sponsored by a SCSI component company or listing a SCSI company as a collaborator. New trials and material changes to ongoing trials are reported here when they are recorded by the FDA. Purchasers of our industry report receive real-time email or text alerts of additions or changes to the list below.

Red: Early warning of an FDA record update in progress
Green: Recently updated
Company Brief Title Phase End
Date
[1]
Chg
Date
[2]
Chg Ref More
Info
Aastrom
Biosciences
Ixmyelocel-T in
Heart Failure
2 9/15 - - FDA -
Aastrom
Biosciences
Ixmyelocel-T in
Limb Ischemia
3 3/15 - - FDA -
Advanced
Cell Tech.
MA09-hRPE in
Macular Dystrophy
1/2 1/14 - - FDA -
Advanced
Cell Tech.
hESC-RPE in
Macular Dystrophy
1/2 4/14 - - FDA -
Advanced
Cell Tech.
MA09-hRPE in Dry
Macular Dystrophy
1/2 7/14 - - FDA -
Athersys MultiStem in
Ischemic Stroke
2 11/14 - - FDA -
Athersys
(Pfizer)
MultiStem in
Ulcerative Colitis
2 3/14 - - FDA -
BioTime (No FDA-authorized trials)
BrainStorm
Cell Ther.
MSC-NTF in
ALS
1/2 3/13 - - FDA -
BrainStorm
Cell Ther.
MSC-NTF in
ALS
2 2/14 - - FDA -
Cytomedix
(Aldagen)
ALD-401 in
Ischemic Stroke
2 2/14 - - FDA -
Cytomedix
(Aldagen)
Cord Blood in
Lyso. Storage Dis.
1 12/14 - - FDA -
Cytomedix
(Aldagen)
ALDHbr for Cardiac
Angiogenesis
1 4/21(?) - - FDA -
Cytomedix
(Aldagen)
ALDHbr for Interm.
Claudication
2 2/15 - - FDA -
Cytomedix
(Aldagen)
ALD-101 for
Metab. Diseases
2 11/11 - - FDA Suspended
Cytori ASCs for Myo.
Infarct.
1 11/12 - - FDA -
Cytori ASCs for Myo.
Ischemia
1/2 12/17 3/12/13 Note
A
FDA -
Cytori ASCs for Ischemic
Myocardium
1 1/12 - - FDA -
Cytori ASCs for Myo.
Infarction
2 9/17 - - FDA -
International
Stem Cell
(No FDA-authorized trials)
NeoStem
(Amorcyte)
AMR-001 for Myo.
Infarction
2 6/16 - - FDA -
NeoStem
(Amorcyte)
AMR-001 for Myo.
Infarction
1 3/13 - - FDA -
NeuralStem NSCs for Spinal
Cord Injury
1 2/14 - - FDA -
NeuralStem NSCs for ALS 1 6/13 - - FDA -
Osiris Prochymal for
Myo. Infarction
2 2/13 - - FDA -
Osiris Prochymal for
Crohn's Disease
3 6/14 - - FDA -
Osiris Prochymal for
T1 Diabetes
2 12/10 - - FDA Status
unknown
Osiris Prochymal for
Crohn's Disease
3 12/15 - - FDA -
Pluristem PLX-PAD after
Hip Arthroplasty
1/2 3/14 - - FDA -
Pluristem PLX-PAD for Interm.
Claudication
2 12/15 - - FDA -
StemCells HuCNS-SC for PMD 1 12/12 - - FDA -
StemCells HuCNS-SC for Macular
Degeneration
1/2 3/14 - - FDA -
StemCells HuCNS-SC for Spinal
Cord Injury
1/2 3/16 - - FDA -
StemCells MSCs for Renal
Failure
1/2 11/12 - - FDA -
ThermoGenesis BM-MNCs for
Limb Ischemia
1/2 4/13 - - FDA -
ThermoGenesis BM-MNCs for
Limb Ischemia
1/2 12/12 - - FDA -

1. "End Date" is the "estimated completion date" most recently provided by the sponsor to the FDA. Dates occurring in the past indicate that the trial has not yet completed and the sponsor has not yet updated this information.
2. Date of the most recent material change to this table (see "Chg" column) since inception on 3/8/13.

Change Notes:
Note A: FDA record update in progress. There may be a delay of a few days to a few weeks before the updated study information is available. Please check back, or be the first to know: purchasers of our industry report receive real-time email or text notifications.